ESPR

Esperion to Participate in Upcoming June Investor Conferences

Retrieved on: 
torsdag, maj 23, 2024
Conference, Patient, Esperies, ESPR, ANN, Health, Risk

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website .

Key Points: 
  • ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website .
  • Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m.
  • Live webcasts can be accessed on the investor and media section of the Esperion website .
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

Retrieved on: 
måndag, maj 20, 2024
LDL, Patient, ATP, Hypercholesterolemia, Esperion Therapeutics, Liver, Therapy, ESPR, Safety, Week, ANN, Adenosine triphosphate, Pharmaceutical industry

The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.

Key Points: 
  • The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.
  • Bempedoic acid is marketed for the treatment of hypercholesterolemia and cardiovascular risk reduction in several regions of the world, including the United States and Europe.
  • In 2020, Otsuka acquired exclusive development and commercialization rights for bempedoic acid in Japan from Esperion and is currently developing it domestically.
  • Trial participants were administered either 180 mg of bempedoic acid or a placebo, orally, once a day, for 12 weeks to evaluate the efficacy and safety of bempedoic acid.

Glimpact Launches First Digital Platform for American Companies to Evaluate Overall Environmental Footprint, Measuring 16 Categories of Impact of Human Activity

Retrieved on: 
onsdag, april 24, 2024
Textile, Celio, European Green Deal, Corporate sustainability, Innovation system, European Commission, CSR, Chantelle, Ecological design, Carbon, Climate, Aigle, ESPR, Green Deal, The Green Deal, Legislation, Zalando, Heineken, Civil service commission, PEF, Organization, Renewable energy

Based on the new scientific doctrine of the EU, Glimpact gives American companies complete 360° visibility on their real environmental footprint beyond carbon emissions and global warming.

Key Points: 
  • Based on the new scientific doctrine of the EU, Glimpact gives American companies complete 360° visibility on their real environmental footprint beyond carbon emissions and global warming.
  • Recognizing that North America lacks comprehensive tools to measure environmental impact beyond carbon emissions, Glimpact intends to bring its pioneering and disruptive approach to environmental footprint analysis to the United States.
  • Glimpact’s technology measures environmental impact using the PEF/OEF (Product Environmental Footprint/Organization Environmental Footprint) method that considers 16 impact categories and nine planetary boundaries.
  • GlimpactScan and MyGlimpact, to promote ecological awareness and share Glimpact’s vision of environmental sustainability with U.S. corporations and consumers.

Esperion to Report First Quarter 2024 Financial Results on May 7

Retrieved on: 
tisdag, april 23, 2024
ANN, Health, Esperies, ESPR, PIN, Patient, Risk

ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Key Points: 
  • ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
  • ET to discuss these financial results and provide business updates.
  • Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
  • A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events .

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
söndag, april 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Retrieved on: 
måndag, april 1, 2024
Health, ANN, Risk, Patient, Esperies, ESPR, FDA, Food, Pharmaceutical industry

ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m.

Key Points: 
  • ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m.
  • ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) recent approval of broad new labels for Esperion’s products.
  • “We are honored to ring the Nasdaq opening bell to celebrate a significant milestone for Esperion,” said Mr. Koenig.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
tisdag, mars 26, 2024
Risk, Health, Patient, ANN, Conference, Esperies, ESPR, Broadcasting

ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference.
  • Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET.
  • The Esperion management team will also host investor meetings that same day.
  • A live audio webcast can be accessed on the investor and media section of the Esperion website .

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
fredag, mars 22, 2024
Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Committee, Spasm, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Esperies, Rupture, FDA, Molina Healthcare, Hypersensitivity, Health, Conference, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Uric acid, Pharmaceutical industry

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
fredag, mars 22, 2024
FDA, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Photograph, Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Webcast, Committee, Spasm, Splenic infarction, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, U.S. FDA, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Rupture, Molina Healthcare, Hypersensitivity, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Multimedia, Uric acid, Dietary supplement

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • View the full release here: https://www.businesswire.com/news/home/20240322544788/en/
    U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Makersite Launches AI-Enabled Ecodesign Dashboard

Retrieved on: 
onsdag, mars 20, 2024
Exercise, Risk, AI, LCA, Carbon, ESPR, Online shopping

STUTTGART, Germany, March 20, 2024 /PRNewswire/ -- Makersite, a software company pioneering a new approach to sustainable product design and sourcing, today launched an AI-enabled Ecodesign Dashboard that helps product designers and engineers make smarter design decisions when considering environmental impacts and cost optimization.

Key Points: 
  • Makersite addresses this with an Ecodesign Dashboard that provides engineers with a trade-off analysis supported by clear, visualized data of the environmental and cost impacts of each component chosen within their design.
  • In addition to streamlining design decision-making, the Makersite Ecodesign Dashboard allows for the exporting of visualizations and data for use in internal systems, corporate and regulatory disclosures, and offline calculations.
  • The dashboard provides AI-enabled lifecycle assessment (LCA) and carbon footprint data that can be shared directly from Makersite with customers and stakeholders.
  • For more information about the Makersite Ecodesign Dashboard, visit https://makersite.io/accelerate-product-design/ai-enabled-ecodesign-usin...